Emmaus Life Sciences (EMMA) AI Stock Analysis

• Market Cap: $957.98K
• Dividend Yield: N/A
• Average Volume (3M): 17.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 54.28
• Revenue Growth: -34.70%
• EPS Growth: 10.06%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 63,865,570
• 10 Day Avg. Volume: 36,154
• 30 Day Avg. Volume: 17,781
• PEG Ratio: 0.04
• Price to Book (P/B): -0.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.52
• Enterprise Value/Market Cap: 105.38
• Enterprise Value/Revenue: 1.37
• Enterprise Value/Gross Profit: 6.56
• Enterprise Value/Ebitda: 446.71
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: $0.00 ▼(-100.00%Downside)

Emmaus Life Sciences' stock is primarily hindered by significant financial performance challenges, including negative revenue growth and financial instability. While technical indicators show short-term positive momentum, the long-term outlook remains weak. The negative P/E ratio and absence of dividend yield further contribute to a low valuation score.

Emmaus Life Sciences Business Overview & Revenue Model

Company Description

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments and therapies for rare and orphan diseases. The company's flagship product is Endari, an FDA-approved treatment for sickle cell disease, which is designed to reduce the acute complications associated with the condition. Emmaus Life Sciences operates within the healthcare sector, specifically targeting hematology and rare disease markets, and is committed to improving the quality of life for patients with unmet medical needs.

How the Company Makes Money

Emmaus Life Sciences primarily generates revenue through the sales of its core product, Endari, which is commercially available in the United States and other international markets. The company also seeks to expand its revenue streams by pursuing regulatory approvals and commercial partnerships in additional regions. Furthermore, Emmaus may engage in research collaborations, licensing agreements, and strategic partnerships to fund and advance its pipeline of potential treatments, contributing to its overall revenues.

Emmaus Life Sciences Financial Statement Overview

Summary

Emmaus Life Sciences is facing critical financial challenges, including declining revenues and persistent losses. The negative equity position and high leverage indicate financial instability and potential solvency risks, despite a high gross profit margin that suggests operational efficiency.

Income Statement

The company has experienced a significant decline in revenue from $29.6 million in 2023 to $16.7 million in 2024, indicating a negative revenue growth rate. Gross profit margin remains high at approximately 92.8% in 2024, suggesting efficient cost management. However, the net profit margin is deeply negative due to substantial net losses, highlighting ongoing profitability challenges.

Balance Sheet

The balance sheet shows high leverage with a negative equity position, as indicated by a debt-to-equity ratio that cannot be calculated meaningfully due to negative equity. The substantial total debt of $33.1 million in 2024 is concerning given the negative stockholders' equity, suggesting financial instability and potential solvency risks.

Cash Flow

Operating cash flow is consistently negative, though the free cash flow improved slightly from -$1.52 million in 2023 to -$2.30 million in 2024. The operating cash flow to net income ratio suggests that cash outflows are less than the net losses, reflecting some control over cash management despite ongoing cash burn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.55M	16.65M	29.60M	18.39M	20.61M	23.17M
Gross Profit	15.38M	15.45M	28.25M	15.80M	17.30M	20.92M
EBITDA	464.00K	-910.00K	3.62M	-5.50M	-12.76M	7.02M
Net Income	-4.43M	-6.45M	-3.73M	-10.63M	-15.95M	1.35M
Balance Sheet
Total Assets	22.48M	23.60M	35.18M	48.23M	56.73M	59.27M
Cash, Cash Equivalents and Short-Term Investments	1.33M	1.39M	2.55M	2.02M	2.28M	2.49M
Total Debt	32.98M	33.13M	32.65M	25.10M	29.91M	18.99M
Total Liabilities	81.08M	80.08M	82.94M	82.32M	78.18M	64.69M
Stockholders Equity	-58.60M	-56.48M	-47.76M	-34.09M	-21.45M	-5.42M
Cash Flow
Free Cash Flow	-2.15M	-2.30M	-1.52M	-5.10M	-1.33M	-28.63M
Operating Cash Flow	-2.15M	-2.29M	-1.50M	-5.07M	-1.25M	-2.45M
Investing Cash Flow	2.50M	2.50M	-432.00K	-2.39M	-6.38M	5.47M
Financing Cash Flow	-743.00K	-1.35M	2.48M	7.23M	7.41M	-2.31M

Emmaus Life Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EMMA, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 75.43 is Negative, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EMMA.

Emmaus Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
GRI	45 Neutral	$2.98M	―	-468.00%	―	―	98.55%
EMMA	44 Neutral	$957.98K	―	6.50%	―	-34.70%	10.06%
ONCO	33 Underperform	$2.52M	―	-237.69%	―	―	-97.16%
SLRX	30 Underperform	$2.11M	―	-300.16%	―	―	79.57%
PCSA	29 Underperform	$5.14M	―	-192.72%	―	―	56.26%
SCPX	23 Underperform	$508.27K	―	-174.06%	―	-10.75%	82.25%